A novel antihuman C3d monoclonal antibody with specificity to the C3d complement split product.
The complement component C3 and the cleavage products of C3b/iC3b, C3c and C3d are used as biomarkers in clinical diagnostics. Currently, no specific antibodies are able to differentiate C3d from other fragments, although such a distinction could be very valuable considering that they may reflect different pathophysiological mechanisms. We have developed a rat antihuman C3d monoclonal antibody with specificity to the end sequence of the N-terminal region of C3d. The antibody can therefore only bind to C3d when it manifests itself as the final end product of cleaved C3. We believe that this specificity is it first of its kind, and predicts that it can be used as a detection tool in several immunological methods with great value in diagnostics.
Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark.
Karina Juhl
KJ
Rasmussen
Department of Clinical Immunology, University Hospital of Copenhagen, Rigshospitalet, Denmark.
Mikkel-Ole
MO
Skjoedt
Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark.
Lars
L
Vitved
Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark.
Karsten
K
Skjoedt
Unit for Thrombosis Research, Institute of Public Health, University of Southern Denmark, Esbjerg, Denmark. Electronic address: ypalarasah@health.sdu.dk.
Yaseelan
Y
Palarasah
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000276:immunology*; D000918:Antibody Specificity; D001666:Binding Sites, Antibody; D003167:Complement Activation; D015933:Complement C3d / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007114:Immunization; D007279:Injections, Subcutaneous; D011485:Protein Binding; D054730:Protein Interaction Domains and Motifs; D017207:Rats, Sprague-Dawley
D000911:Antibodies, Monoclonal; D015933:Complement C3d
C3d; Clinical diagnostic; End specificity; Monoclonal antibody